- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02090296
Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study
October 16, 2017 updated by: Emily Riehm Meier, Children's National Research Institute
Reticulocyte as Risk Marker: Targeted Therapy for Infants With Sickle Cell Anemia
Sickle cell anemia (SCA) patients experience organ damage that begins at an early age and results in significant morbidity and early mortality.
Although all SCA patients share the same genetic mutation, the clinical complications are highly variable with some patients experiencing frequent and severe complications, while others have few serious complications.
If SCA severity could be predicted early in life, those patients at greatest risk for complications could receive treatment prior to the onset of organ damage.
No general SCA severity predictor or one that can be informative early in life exists.
The investigators preliminary research has identified the absolute reticulocyte count (ARC) as a potential early predictive risk marker for SCA complications in pediatric patients.
A higher ARC between ages 2 and 6 months of age is associated with an increased risk of hospitalization in the first 3 years of life; the mean ARC for the 36 patients who were hospitalized for SCA complications was significantly higher than that of the remaining 23 in those who were not hospitalized.
Moreover, total hospitalizations were nearly three times higher by age 2 years in those infants who had an ARC of > 200 than for those infants whose ARC was <200.
The proposed study will determine if ARC can be used as a risk-stratifier in asymptomatic infants with SCA and ascertain its value in targeting hydroxyurea therapy to those infants at highest risk of SCA sequelae.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, D.C., District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 1 year (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ages 6-12 months
- Sickle cell anemia (HbSS)
- steady state absolute reticulocyte count between 2-6 months is available in the medical record
Exclusion Criteria:
- receiving hydroxyurea or chronic monthly blood transfusions
- patient enrolled in preliminary study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Sugar water
Placebo arm
|
Other Names:
|
ACTIVE_COMPARATOR: Hydroxyurea
Treatment Arm
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sickle Cell Clinical Change from Baseline to Study Completion ( 18 months)
Time Frame: Every 4 weeks for the 18 months study duration
|
Participants will be have a study visit at baseline and then every month for the 18 month duration of the study.
Study visits will include a physical exam, laboratory monitoring and interval history to assess the change (if any) every 4 weeks of sickle cell complications.
|
Every 4 weeks for the 18 months study duration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (ACTUAL)
June 1, 2015
Study Completion (ACTUAL)
June 1, 2015
Study Registration Dates
First Submitted
February 4, 2014
First Submitted That Met QC Criteria
March 14, 2014
First Posted (ESTIMATE)
March 18, 2014
Study Record Updates
Last Update Posted (ACTUAL)
October 18, 2017
Last Update Submitted That Met QC Criteria
October 16, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RBTSCA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Anemia
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationSickle Cell Anemia | Sickle Beta Thalassemia | Sickle Cell Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Pain | Hbss | Hbsc | Sickle Cell Syndrome VariantUnited States
-
Brown UniversityNational Heart, Lung, and Blood Institute (NHLBI); NovartisRecruitingSickle Cell Disease | Sickle Cell Anemia in ChildrenAngola
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
Beni-Suef UniversityUniversity of Arizona; Maternity and Children Hospital, Makkah; Benisuef university...CompletedSickle Cell Disease | Vaso-occlusive Crisis | Sickle Cell Anemia in ChildrenEgypt, Saudi Arabia
-
National Institute of Diabetes and Digestive and...RecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell TraitUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
Global Health Uganda LTDEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingSickle Cell Anemia in ChildrenUganda
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States